Relay Therapeutics, Inc. (RLAY): Capital Expenditures
$410.0K
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
-64.4%
3-year compound annual growth
-26.6%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $410.0K | -79.7% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $2.02M | -51.1% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $4.13M | -54.5% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $9.06M | +161.1% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $3.47M | +79.8% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $1.93M | -75.9% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $8.00M | n/a | 2022-02-24, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $410.0K | -79.7% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $522.0K | -7.6% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $99.0K | n/a |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $827.0K | +76.7% |
| Alector, Inc. (ALEC) | 2025-12-31 | $41.0K | -96.7% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $1.36M | -72.2% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $4.41M | +15.2% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $293.5K | +999.2% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $738.0K | +97.3% |
Compare RLAY, LCTX, PTHS, LENZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗